Analytical Chemistry and Pharmacology Core Facility

分析化学和药理学核心设施 这一核心的目标是通过分析化学和药理学基础设施和方法支持小分子和纳米抗癌药物的翻译开发。分子治疗计划的扩大，用于评估抗癌药物的临床前模型的开发，以及新的北卡罗来纳州肿瘤医院临床试验单位的开设，创造了 对应用药理学服务的需求。Zamboni博士的招聘和癌症中心机构资金的大量投入启动了核心及其运营。这一新的核心由转化肿瘤学和纳米药物开发倡议(TOND2I)实验室(2009年3月开放)和UNC GLP生物分析设施(将于2月10日开放)组成。这一核心提供的技术和资源以前在北卡罗来纳大学是没有的。此外，北卡罗来纳大学的普洛斯生物分析设施是少数几个存在于学术中心的普洛斯实验室之一。核心资源将通过在执行分析和药理学研究方面提供杰出的专业知识来扩大研究人员的视野和资金，提供 最高质量的数据，并以具有成本效益的方式进行这些研究。 核心信息/信息包括：GLP和非GLP级别的分析研究；药物配方的开发；生物基质分析分析的开发和验证；样品分析；药代动力学和药效学数据分析；以及纳米颗粒药理学的专门方法。这方面的一个例子是与夏普莱斯、Collichio和Ollila博士的合作，我们目前正在评估影响抗癌药物在黑色素瘤异种移植和基因工程小鼠模型(GEMM)以及皮肤黑色素瘤患者中肿瘤递送的因素。 未来的计划是扩大对北卡罗来纳大学LCCC成员的研究，并利用这个核心的资源为北卡罗来纳大学招募新的抗癌药物。核心中心要求160,846美元，占其运营成本的15%；癌症中心成员占核心用户的96%。这个新的核心将是该中心的一笔巨大资产。

Analytical Chemistry and Pharmacology Core Facility The goal of this core is to support the translational development of small molecule and nanoparticle anticancer agents via analytical chemistry and pharmacologic infrastructure and methodologies. The expansion of the MolecularTherapeutics Program, development of preclinical models used to evaluate anticancer agents and the opening of new North Carolina Cancer Hospital's Clinical Trials Unit created the demand for applied pharmacology services. The recruitment of Dr. Zamboni and the substantial investment of cancer center institutional funds launched the core and its operations. This new core is comprised of the Translational Oncology and Nanoparticle Drug Development Initiative (TOND2I) Lab (opened in March'09) and the UNC GLP Bioanalytical Facility (will open in Feb'10). The technologies and resources offered by this core were not previously available at UNC. Moreover, the UNC GLP Bioanalytical Facility is one of the few such GLP labs that exist in an academic center. The core resources will expand researchers' horizons and funding by providing outstanding expertise in performing analytical and pharmacology studies, providing the highest quality of data and performing these studies in a cost effective manner. The core's sen/ices consist of: analytical studies at GLP and non-GLP levels; development of drug formulations; development and validation of analytical assays In biological matrices; sample analysis; pharmacokinetic and pharmacodynamic data analysis; and specialized methods for nanoparticle pharmacology. An example of this is the collaboration with Drs. Sharpless, Collichio and Ollila, where we are currently evaluating the factors affecting the tumor delivery of anticancer agents in xenograft and genetically engineered mouse models (GEMM) of melanoma and in patients with cutaneous melanoma. Future plans are to expand the research of UNC LCCC members and use the resources of this core to recruit novel anticancer agents to UNC. The core requests $160,846, representing 15% of its operating costs; Cancer Center members constitute 96% of the core's users. This new core will be a tremendous asset to the center.